Exact Mass: 437.1423
Exact Mass Matches: 437.1423
Found 445 metabolites which its exact mass value is equals to given mass value 437.1423
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Fluphenazine
Fluphenazine is only found in individuals that have used or taken this drug. It is a phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine. [PubChem]Fluphenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent
7-(1,2,3,4,4a,5,7,7a-Octahydropyrrolo[3,4-b]pyridin-6-yl)-1-cyclopropyl-6-fluoranyl-8-methoxy-4-oxidanylidene-quinoline-3-carboxylic acid hydrochloride
Alobresib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholine
(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholine is a metabolite of aprepitant. Aprepitant (Emend) is an antiemetic chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by blocking the neurokinin 1 (NK1) receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003. (Wikipedia)
N-(4-(2-Chlorophenyl)-6,7-dimethyl-3-quinolyl)-N'-(2,4-difluorophenyl)urea
N-Acetylcochinol-O-phosphate
Aleglitazar
(S)-2-[(S)-2-((S)-2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-succinic acid
Estromustine
Isavuconazole
Pazopanib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor
Ravuconazole
(2S)-2-[[(2S)-2-[[(2S)-2-Amino-3-methylbutanoyl]amino]propanoyl]-phenylmethoxycarbonylamino]butanedioic acid
Ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate
N-[2-[(R)-[3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-pyrrol-3-yl]benzamide
(E)-3-(methylsulfonyl)-propenoic acid (2E,6E)-3-hydroxy-4-(8-hydroxy-3,7-dimethyl-2,6-octadienyloxy)-phenethyl amide|sakerinol A
jatropham 5-O-3)-beta-D-glucopyranoside>|Jatropham 5-O-beta-D-glucopyranosyl-(1->3)-beta-D-glucopyranoside
(3S,4R,5S)-4-ethenyl-3-(beta-D-glucopyranosyloxy)-4,4a,5,6,7,8-hexahydro-8-oxo-3H-pyrano[3,4-c]pyridine-6-sulfonic acid
(E)-3-(methylsulfonyl)-propenoic acid (2E,6E)-2-[4-(8-hydroxy-3,7-dimethyl-2,6-octadienyloxy)-phenyl]-2-hydroxyethyl amide|beta-hydroxygerambullol|??-Hydroxygerambullol
WWL70
WWL70 is a selective alpha/beta hydrolase domain 6 (ABHD6) inhibitor with an IC50 of 70 nM.
Hysco
Scopolamine hydrobromide trihydrate appears as white orthorhombic sphenoidal crystals from water. pH of 0.05 molar solution: 5.85. (NTP, 1992) Scopolamine hydrobromide trihydrate is a hydrate that is the trihydrate form of scopolamine hydrobromide. It has a role as a mydriatic agent, a muscarinic antagonist, an anaesthesia adjuvant, an antispasmodic drug and an antiemetic. It contains a scopolamine hydrobromide (anhydrous). Scopolamine Hydrobromide is the hydrobromide salt form of scopolamine, a tropane alkaloid derived from plants of the nightshade family (Solanaceae), specifically Hyoscyamus niger and Atropa belladonna, with anticholinergic, antiemetic and antivertigo properties. Structurally similar to acetylcholine, scopolamine antagonizes acetylcholine activity mediated by muscarinic receptors located on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. The agent is used to cause mydriasis, cycloplegia, to control the secretion of saliva and gastric acid, to slow gut motility, and prevent vomiting. An alkaloid from SOLANACEAE, especially DATURA and SCOPOLIA. Scopolamine and its quaternary derivatives act as antimuscarinics like ATROPINE, but may have more central nervous system effects. Its many uses include an anesthetic premedication, the treatment of URINARY INCONTINENCE and MOTION SICKNESS, an antispasmodic, and a mydriatic and cycloplegic. C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D009184 - Mydriatics C78283 - Agent Affecting Organs of Special Senses > C29706 - Mydriatic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents
Pazopanib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor
Fluphenazine (oxide)
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent
Ala Ala Asn Tyr
Ala Ala Tyr Asn
Ala Cys Met Asn
Ala Cys Asn Met
Ala Phe Asn Ser
Ala Phe Ser Asn
Ala Gly Gln Tyr
Ala Gly Tyr Gln
Ala Met Cys Asn
Ala Met Asn Cys
Ala Asn Ala Tyr
Ala Asn Cys Met
Ala Asn Phe Ser
Ala Asn Met Cys
Ala Asn Ser Phe
Ala Asn Tyr Ala
Ala Gln Gly Tyr
Ala Gln Tyr Gly
Ala Ser Phe Asn
Ala Ser Asn Phe
Ala Tyr Ala Asn
Ala Tyr Gly Gln
Ala Tyr Asn Ala
Ala Tyr Gln Gly
Cys Ala Met Asn
Cys Ala Asn Met
Cys Cys Gly Arg
Cys Cys Asn Val
Cys Cys Arg Gly
Cys Cys Val Asn
Cys Asp Asn Ser
Cys Asp Ser Asn
Cys Gly Cys Arg
Cys Gly Lys Met
Cys Gly Met Lys
Cys Gly Met Gln
Cys Gly Gln Met
Cys Gly Arg Cys
Cys Lys Gly Met
Cys Lys Met Gly
Cys Met Ala Asn
Cys Met Gly Lys
Cys Met Gly Gln
Cys Met Lys Gly
Cys Met Asn Ala
Cys Met Gln Gly
Cys Asn Ala Met
Cys Asn Cys Val
Cys Asn Asp Ser
Cys Asn Met Ala
Cys Asn Ser Asp
Cys Asn Thr Thr
Cys Asn Val Cys
Cys Gln Gly Met
Cys Gln Met Gly
Cys Gln Ser Thr
Cys Gln Thr Ser
Cys Arg Cys Gly
Cys Arg Gly Cys
Cys Ser Asp Asn
Cys Ser Asn Asp
Cys Ser Gln Thr
Cys Ser Thr Gln
Cys Thr Asn Thr
Cys Thr Gln Ser
Cys Thr Ser Gln
Cys Thr Thr Asn
Cys Val Cys Asn
Cys Val Asn Cys
Asp Cys Asn Ser
Asp Cys Ser Asn
Asp Asn Cys Ser
Asp Asn Ser Cys
Asp Ser Cys Asn
Asp Ser Asn Cys
Phe Ala Asn Ser
Phe Ala Ser Asn
Phe Gly Asn Thr
Phe Gly Gln Ser
Phe Gly Ser Gln
Phe Gly Thr Asn
Phe Asn Ala Ser
Phe Asn Gly Thr
Phe Asn Ser Ala
Phe Asn Thr Gly
Phe Gln Gly Ser
Phe Gln Ser Gly
Phe Ser Ala Asn
Phe Ser Gly Gln
Phe Ser Asn Ala
Phe Ser Gln Gly
Phe Thr Gly Asn
Phe Thr Asn Gly
Gly Ala Gln Tyr
Gly Ala Tyr Gln
Gly Cys Cys Arg
Gly Cys Lys Met
Gly Cys Met Lys
Gly Cys Met Gln
Gly Cys Gln Met
Gly Cys Arg Cys
Gly Phe Asn Thr
Gly Phe Gln Ser
Gly Phe Ser Gln
Gly Phe Thr Asn
Gly Lys Cys Met
Gly Lys Met Cys
Gly Met Cys Lys
Gly Met Cys Gln
Gly Met Lys Cys
Gly Met Gln Cys
Gly Asn Phe Thr
Gly Asn Thr Phe
Gly Gln Ala Tyr
Gly Gln Cys Met
Gly Gln Phe Ser
Gly Gln Met Cys
Gly Gln Ser Phe
Gly Gln Tyr Ala
Gly Arg Cys Cys
Gly Ser Phe Gln
Gly Ser Gln Phe
Gly Thr Phe Asn
Gly Thr Asn Phe
Gly Tyr Ala Gln
Gly Tyr Gln Ala
Lys Cys Gly Met
Lys Cys Met Gly
Lys Gly Cys Met
Lys Gly Met Cys
Lys Met Cys Gly
Lys Met Gly Cys
Met Ala Cys Asn
Met Ala Asn Cys
Met Cys Ala Asn
Met Cys Gly Lys
Met Cys Gly Gln
Met Cys Lys Gly
Met Cys Asn Ala
Met Cys Gln Gly
Met Gly Cys Lys
Met Gly Cys Gln
Met Gly Lys Cys
Met Gly Gln Cys
Met Lys Cys Gly
Met Lys Gly Cys
Met Asn Ala Cys
Met Asn Cys Ala
Met Asn Ser Ser
Met Gln Cys Gly
Met Gln Gly Cys
Met Ser Asn Ser
Met Ser Ser Asn
Asn Ala Ala Tyr
Asn Ala Cys Met
Asn Ala Phe Ser
Asn Ala Met Cys
Asn Ala Ser Phe
Asn Ala Tyr Ala
Asn Cys Ala Met
Asn Cys Cys Val
Asn Cys Asp Ser
Asn Cys Met Ala
Asn Cys Ser Asp
Asn Cys Thr Thr
Asn Cys Val Cys
Asn Asp Cys Ser
Asn Asp Ser Cys
Asn Phe Ala Ser
Asn Phe Gly Thr
Asn Phe Ser Ala
Asn Phe Thr Gly
Asn Gly Phe Thr
Asn Gly Thr Phe
Asn Met Ala Cys
Asn Met Cys Ala
Asn Met Ser Ser
Asn Ser Ala Phe
Asn Ser Cys Asp
Asn Ser Asp Cys
Asn Ser Phe Ala
Asn Ser Met Ser
Asn Ser Ser Met
Asn Thr Cys Thr
Asn Thr Phe Gly
Asn Thr Gly Phe
Asn Thr Thr Cys
Asn Val Cys Cys
Asn Tyr Ala Ala
Gln Ala Gly Tyr
Gln Ala Tyr Gly
Gln Cys Gly Met
Gln Cys Met Gly
Gln Cys Ser Thr
Gln Cys Thr Ser
Gln Phe Gly Ser
Gln Phe Ser Gly
Gln Gly Ala Tyr
Gln Gly Cys Met
Gln Gly Phe Ser
Gln Gly Met Cys
Gln Gly Ser Phe
Gln Gly Tyr Ala
Gln Met Cys Gly
Gln Met Gly Cys
Gln Ser Cys Thr
Gln Ser Phe Gly
Gln Ser Gly Phe
Gln Ser Thr Cys
Gln Thr Cys Ser
Gln Thr Ser Cys
Gln Tyr Ala Gly
Gln Tyr Gly Ala
Arg Cys Cys Gly
Arg Cys Gly Cys
Arg Gly Cys Cys
Ser Ala Phe Asn
Ser Ala Asn Phe
Ser Cys Asp Asn
Ser Cys Asn Asp
Ser Cys Gln Thr
Ser Cys Thr Gln
Ser Asp Cys Asn
Ser Asp Asn Cys
Ser Phe Ala Asn
Ser Phe Gly Gln
Ser Phe Asn Ala
Ser Phe Gln Gly
Ser Gly Phe Gln
Ser Gly Gln Phe
Ser Met Asn Ser
Ser Met Ser Asn
Ser Asn Ala Phe
Ser Asn Cys Asp
Ser Asn Asp Cys
Ser Asn Phe Ala
Ser Asn Met Ser
Ser Asn Ser Met
Ser Gln Cys Thr
Ser Gln Phe Gly
Ser Gln Gly Phe
Ser Gln Thr Cys
Ser Ser Met Asn
Ser Ser Asn Met
Ser Thr Cys Gln
Ser Thr Gln Cys
Thr Cys Asn Thr
Thr Cys Gln Ser
Thr Cys Ser Gln
Thr Cys Thr Asn
Thr Phe Gly Asn
Thr Phe Asn Gly
Thr Gly Phe Asn
Thr Gly Asn Phe
Thr Asn Cys Thr
Thr Asn Phe Gly
Thr Asn Gly Phe
Thr Asn Thr Cys
Thr Gln Cys Ser
Thr Gln Ser Cys
Thr Ser Cys Gln
Thr Ser Gln Cys
Thr Thr Cys Asn
Thr Thr Asn Cys
Val Cys Cys Asn
Val Cys Asn Cys
Val Asn Cys Cys
6-Hydroxy Doxazosin
Tyr Ala Ala Asn
Tyr Ala Gly Gln
Tyr Ala Asn Ala
Tyr Ala Gln Gly
Tyr Gly Ala Gln
Tyr Gly Gln Ala
Tyr Asn Ala Ala
Tyr Gln Ala Gly
Tyr Gln Gly Ala
Moxifloxacin HCl
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D004791 - Enzyme Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
[(2R,3S,4R,5R,6R)-3,4-diacetyloxy-5-(1,3-dioxoisoindol-2-yl)-6-fluorooxan-2-yl]methyl acetate
Ravuconazole
C254 - Anti-Infective Agent > C514 - Antifungal Agent
(4-nitrophenyl) (2S)-6-amino-2-(phenylmethoxycarbonylamino)hexanoate,hydrochloride
(4E)-5-{4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl}-(3S)-3-hydroxy-4-pentenoic acid
4-[(2-chloro-4,6-dinitrophenyl)azo]-N,N-diethyl-2,5-dimethoxyaniline
O,O-Diethylphosphoryl (Z)-2-(2-aminothiazol-4-yl)-2-(tert-Butoxycarbonylmethoxyimino)acetate
N-ALPHA-DANSYL-L-TRYPTOPHAN CYCLOHEXYLAMMONIUM SALT
(2S,3R)-2-((S)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)Morpholine
2-Thiophenecarboxamide, 5-chloro-N-[3-[[3,5-dimethyl-4-(3-oxo-4-morpholinyl)phenyl]amino]-2-hydroxypropyl]
Cimetropium bromide
Cimetropium Bromide (DA-3177) is a mAChR antagonist for long-term treatment of irritable bowel syndrome.
benzyl 2-acetamido-2-deoxy-3,4,6-tri-o-acetyl-beta-d-glucopyranoside
Aleglitazar
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C154291 - Peroxisome Proliferator-Activated Receptor Agonist
2-(9H-FLUOREN-9-YLMETHOXYCARBONYLAMINO)-3-NAPHTHALEN-2-YL-PROPIONIC ACID
Oxolamine citrate
D019141 - Respiratory System Agents > D000996 - Antitussive Agents D002491 - Central Nervous System Agents
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-2,6-difluoro-alpha-methyl-L-phenylalanine
Fominoben hydrochloride
(R)-3-((((9H-FLUOREN-9-YL)METHOXY)CARBONYL)AMINO)-4-(3,4-DIFLUOROPHENYL)BUTANOIC ACID
Fmoc-(S)-3-Amino-4-(3,4-Difluoro-Phenyl)-Butyric Acid
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-Methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride (1:1), rel-
2-DEOXY-2-PHTHALIMIDO-3,4,6-TRI-O-ACETYL-ALPHA-D-GALACTOPYRANOSYL FLUORIDE
(2R,3S)-2-((R)-1-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholine
(2R)-3-(3-chloro-4-hydroxyphenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
Isavuconazole
J - Antiinfectives for systemic use > J02 - Antimycotics for systemic use > J02A - Antimycotics for systemic use > J02AC - Triazole and tetrazole derivatives D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C254 - Anti-Infective Agent > C514 - Antifungal Agent
4-(4-Chloro-3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carboxamido)-2,6-difluorobenzoic acid
C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids
N-Acetylcochinol-O-phosphate
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent
Ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate
(6-Chloro-1-(2-(dimethylamino)ethyl)indol-3-yl)-spiro(1H-isobenzofuran-3,4-piperidine)-1-yl-methanone
Ipsapirone hydrochloride
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist
2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid
4-(Carbamoylamino)benzoic acid [2-(3-chloro-4-methylanilino)-2-oxo-1-phenylethyl] ester
N-[1,4-dioxo-3-(4-phenyl-1-piperazinyl)-2-naphthalenyl]benzamide
N-(2-furanylmethyl)-1-[2-(2-hydroxyethoxy)ethyl]-2-imino-10-methyl-5-oxo-3-dipyrido[3,4-c:1,2-f]pyrimidinecarboxamide
1,3-Dimethyl-8-[methyl-(phenylmethyl)amino]-7-[2-(2-pyrimidinylthio)ethyl]purine-2,6-dione
1-(3-(2,4-Dimethylthiazol-5-YL)-4-oxo-2,4-dihydroindeno[1,2-C]pyrazol-5-YL)-3-(4-methylpiperazin-1-YL)urea
Meropenem Hydrate
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D013845 - Thienamycins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
N-Acetylcochinol-O-phosphate
(S)-2-[(S)-2-((S)-2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-succinic acid
(E)-1-(glutathion-S-yl)-N-hydroxy-omega-(methylsulfanyl)butan-1-imine
N-[2-[(R)-[3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-pyrrol-3-yl]benzamide
(2S)-2-[[(2S)-2-[[(2S)-2-Amino-3-methylbutanoyl]amino]propanoyl]-phenylmethoxycarbonylamino]butanedioic acid
4-[5-(3-Methoxyphenyl)-3-(4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide
4-({[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl]methylene}amino)-5-(4-pyridinyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
6-[2-(2-methoxyphenyl)imino-3-(2-oxolanylmethyl)-4-thiazolyl]-4H-1,4-benzoxazin-3-one
N4-cyclohexyl-N1-ethyl-N4-(2-pyridinylmethyl)benzene-1,4-disulfonamide
2-[7-chloro-2,3-dioxo-4-(phenylmethyl)-1-quinoxalinyl]-N-(3-fluorophenyl)acetamide
N-[2-(3-chlorophenyl)ethyl]-2-[[3-cyano-6-(3-methoxyphenyl)-2-pyridinyl]thio]acetamide
N-(5-phenyl-1,3,4-thiadiazol-2-yl)-2-[[4-propyl-5-(2-pyridinyl)-1,2,4-triazol-3-yl]thio]acetamide
1-(4-fluorophenyl)-3-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]thiourea
3-(2,3-dimethoxyphenyl)-1-(9-methyl-2-phenyl-9H-imidazo[1,2-a]benzimidazol-3-yl)prop-2-en-1-one
2-[(1S,3R,4aR,9aS)-6-[(4-fluorophenyl)sulfonylamino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]acetic acid
2-[(1R,3R,4aR,9aS)-6-[(4-fluorophenyl)sulfonylamino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
2-[(1R,3S,4aS,9aR)-6-[(4-fluorophenyl)sulfonylamino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
(6S,7R,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7R,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
2-[(1S,3S,4aS,9aR)-6-[(4-fluorophenyl)sulfonylamino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
(6R,7R,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7S,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7R,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7S,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
1-[(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-2-methylsulfonyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
1-[(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-2-methylsulfonyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
1-[(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-methylsulfonyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
1-[(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-methylsulfonyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
(2R,4S)-2-[(1R)-1-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-2-(butylamino)-2-oxoethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylate
3-(3,4-dimethoxyphenyl)-N-{2-[3-methoxy-4-(sulfooxy)phenyl]ethyl}prop-2-enimidic acid
CTX-0294885
CTX-0294885 is a broad spectrum kinase inhibitor that can capture 235 kinases from MDA-MB-231 cells, and can capture all members of the AKT family. CTX-0294885 is a powerful reagent for analysis of kinome signaling networks that can be used for the research of diseases like inflammation, diabetes, and cancer[1].
GW438014A
GW438014A is a potent and selective NPY-Y5 receptor antagonist. GW438014A inhibits food intake and reduces body weight gain in obese rodents[1].
n-(2-hydroxy-2-{4-[(8-hydroxy-3,7-dimethylocta-2,6-dien-1-yl)oxy]phenyl}ethyl)-3-methanesulfonylprop-2-enimidic acid
2-amino-n-(1-{[3-(dichloromethyl)-6,8-dihydroxy-3-methyl-1-oxo-4a,5,6,7-tetrahydro-4h-2-benzopyran-4-yl]-c-hydroxycarbonimidoyl}ethyl)propanimidic acid
(1s)-1-(8-hydroxy-3-{[(1z)-3-methoxy-3-oxoprop-1-en-1-yl]carbamoyl}-9h-pyrido[3,4-b]indol-1-yl)ethyl (2z)-2-methylbut-2-enoate
β-hydroxygerambullol
{"Ingredient_id": "HBIN018158","Ingredient_name": "\u03b2-hydroxygerambullol","Alias": "NA","Ingredient_formula": "C22H31NO6S","Ingredient_Smile": "CC(=CCOC1=CC=C(C=C1)C(CNC(=O)C=CS(=O)(=O)C)O)CCC=C(C)CO","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10139","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}